Congress Materials – Muscular Dystrophy Association Clinical and Scientific Conference (MDA 2026)
2026 Muscular Dystrophy Association Clinical and Scientific Conference | March 8-11 | Orlando, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching (EPIC)
Srikanth Muppidi, Andrea Corse, Heinz Wiendl, Ibrahim Turkoz, Ruben Faelens, Zia Choudhry, Jack Sheehan, Maria Ait-Tihyaty, Nolan Campbell
This document will be available on March 9 2026
Long-term Safety And Efficacy Results of Nipocalimab in Adolescents with Generalized Myasthenia Gravis: vibrance-mg Phase 2/3 Study
Jonathan Strober, MD; Shawn Black, PhD; Marie Fitzgibbon, MPharm, PhD; Saunder Bernes, MD; Akiyuki Uzawa, MD, PhD; Yasuhiro Kimoto, MD; Keiko Ishigaki, MD, PhD; Tuan Vu, MD; Erin E. Neil Knierbein, DO; Hideki Shimomura, MD, PhD; Erik H Niks, MD, PhD; Dan Huang, MSc; Yaowei Zhu, PhD; Sindhu Ramchandren, MD, MS
This document will be available on March 9 2026
POST-HOC Analysis Of Clinically Relevant Anti-vaccine and Anti-virus Antibodies In Patients Treated With Nipocalimab In VIVACITY-MG3 Study
Faye Yu, BSc; Eugene Myshkin, PhD; Sindhu Ramchandren, MD; Ricardo Rojo Cella, MD; Robert Edwards, MPH; Matthew J. Loza, PhD; Dessislava Dimitrova, MD, PhD; Carolyn Cuff, PhD; Sheng Gao, PhD
This document will be available on March 9 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.